Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 113 of 1,261
  1. US 12006298

    Polymorphic compounds and uses thereof

    Aldeyra Therapeutics, Inc. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  2. US 12006355

    Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

    The Regents of the University of California Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  3. US 12006365

    Human anti-semaphorin 4D antibody

    VACCINEX, INC. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  4. US 12005115

    Epstein-barr virus vaccines

    The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  5. US 12006522

    Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene

    Precision BioSciences, Inc. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  6. US 12005126

    Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption

    ALMIRA PHARMA SRL Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  7. US 12005127

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  8. US 12005055

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  9. US 12005123

    Conjugate of isotretinoin and peptide

    CAREGEN CO., LTD. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  10. US 12006363

    Anti-tetraspanin 33 agents and compositions and methods for making and using the same

    BioLegend, Inc. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  11. US 12005124

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  12. US 12005052

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  13. US 12005060

    Ophthalmic formulations of methotrexate

    Aldeyra Therapeutics, Inc. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  14. US 12006341

    Methods of detection and removal of rhabdoviruses from cell lines

    Takeda Vaccines, Inc. Β· Granted Jun 11, 2024 Β· Expires Jun 6, 2044

    granted
  15. US 2024180883

    TREATMENT OF MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] Β· Granted Jun 6, 2024 Β· Expires Jun 1, 2044

    granted
  16. IT 202200024948

    Composti attivatori dei canali potassio KV7.2/KV7.3

    ANGELINI PHARMA S P A [IT] Β· Granted Jun 5, 2024 Β· Expires May 31, 2044

    granted
  17. IT 202200024963

    Composti attivatori dei canali potassio Kv7.2/Kv7.3

    ANGELINI PHARMA S P A [IT] Β· Granted Jun 5, 2024 Β· Expires May 31, 2044

    granted
  18. US 11999720

    Pyrazolylacylpyrazoline compounds and method for treating pain

    United States Government as represented by the Department of Veterans Affairs Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  19. US 11998529

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  20. US 11999748

    Exatecan derivatives, linker-payloads, and conjugates and thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  21. US 11999753

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  22. US 11999747

    Furoquinolinediones as inhibitors of TDP2

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  23. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  24. US 11999796

    Anti-CD70 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.